Sector News

Categories

Borderless Insights

Image
The Skills-Forward Revolution:   Stretching the Boundaries of Professional Flexibility
Image
Sustainability: Business Leaders Must Secure the Long-Term Strategy Despite Short-Term Pressures
Image
Negotiating Terms with a New Employer

Bigger pharma may be scraping for good deals, but Horizon has plenty of options, analysts say

June 29, 2015
Life sciences
Horizon Pharma isn’t exactly the only specialty pharma company hunting for deals. Allergan, Mallinckrodt, Endo and the ever-acquisitive Valeant have all been on shopping sprees lately, leaving some analysts wondering just what’s left worth buying in the space. But Horizon is much smaller than its specialty peers–meaning it’s got plenty of opportunities, UBS analysts figure.
 
In a research report seen by Investor’s Business Daily, UBS’ Marc Goodman and Ami Fadia pointed out that Horizon–with a market cap just over $5 billion–is at least $9 billion smaller than other on-the-prowl specialty pharmas, meaning it’s “playing in a different sandbox.”
 
Because of its track record and balance sheet, Horizon “has hit the radar of more potential sellers of assets,” leading the analysts to up both their price target on the company’s stock and their revenue estimates.
 
That’s music to the ears of CEO Timothy Walbert, who has said he’s building up Horizon’s leadership and infrastructure “to support a larger organization,” the UBS analysts wrote. Recently, that’s involved foraying into the orphan-drug business with a pickup of osteoporosis treatment Actimmune–and following that up with May’s $1.1 billion acquisition of orphan drugmaker Hyperion.
 
And while it may have once looked like Horizon would need new offerings to fill in for Vimovo and Duexis–a pair of flagship products Express Scripts and CVS booted off their preferred formulary lists last year–sales of those drugs have held up, IBD notes, meaning pickups can only boost things further. The analysts credit that to the company’s “prescriptions made easy” sales method, one they say is “really the key differentiating piece for Horizon.”
 
By Carly Helfand
 

comments closed

Related News

July 21, 2024

CordenPharma invests €900m in peptide platform expansion

Life sciences

CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.

Read more
July 21, 2024

DSM-Firmenich to sell MEG-3 fish oil business to KD Pharma Group

Life sciences

DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.

Read more
July 21, 2024

Veranova appoints Cécile Maupas as Senior Vice President, Chief Commercial Officer

Life sciences

Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.

Read more
More news

How can we help you?

We're easy to reach